Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930644 | 0.87 | CCR5 (0.47) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL3635711 | 0.86 | CCR5 (0.44) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL13930663 | 0.86 | CCR5 (0.44) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL3639322 | 0.86 | CCR5 (0.46) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL13930621 | 0.83 | CA1 (0.49) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL13930854 | 0.82 | LMNA (0.50) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL13930632 | 0.82 | CA1 (0.48) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL4254630 | 0.82 | CCR5 (0.43) | LMNAL3MBTL1KDM4ECCR5CA1 | |
| SCHEMBL3639822 | 0.82 | GPR119 (0.47) | CCR5 | |
| SCHEMBL13930656 | 0.80 | LMNA (0.50) | LMNAL3MBTL1KDM4ECCR5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | LMNA 3911/4885L3MBTL1 4818/4885KDM4E 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.